MA28091A1 - Methodes de traitement de la deficience du facteur de croissance de type insuline 1 (1gf-1) - Google Patents

Methodes de traitement de la deficience du facteur de croissance de type insuline 1 (1gf-1)

Info

Publication number
MA28091A1
MA28091A1 MA28924A MA28924A MA28091A1 MA 28091 A1 MA28091 A1 MA 28091A1 MA 28924 A MA28924 A MA 28924A MA 28924 A MA28924 A MA 28924A MA 28091 A1 MA28091 A1 MA 28091A1
Authority
MA
Morocco
Prior art keywords
growth factor
methods
insulin
treatment
below normal
Prior art date
Application number
MA28924A
Other languages
English (en)
Inventor
Ross G Clark
Original Assignee
Tercica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tercica Inc filed Critical Tercica Inc
Publication of MA28091A1 publication Critical patent/MA28091A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des méthodes et des compositions permettant d'accroître les vitesses de croissance, de soulager les symptômes ou d'améliorer le métabolisme de patients humains souffrant d'une déficience du facteur de croissance de type insuline 1 (IGFD). L'invention concerne également des méthodes consistant à administrer un facteur de croissance de type insuline I à un patient dont la grandeur, au moment du traitement ou avant un traitement initial au moyen de IGF-1, est d'au moins environ 2 écarts-types au-dessous de la norme pour un sujet du même âge et du même sexe et dont le niveau sanguin du facteur de croissance de type insuline I, au moment du traitement ou avant le traitement initial au moyen IGF-1, est inférieur à des niveaux moyens normaux, généralement au moins environ 1 écart-type au-dessous des niveaux moyens normaux, pour l'âge et le sexe.
MA28924A 2003-09-12 2006-04-07 Methodes de traitement de la deficience du facteur de croissance de type insuline 1 (1gf-1) MA28091A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50257903P 2003-09-12 2003-09-12

Publications (1)

Publication Number Publication Date
MA28091A1 true MA28091A1 (fr) 2006-08-01

Family

ID=34619295

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28924A MA28091A1 (fr) 2003-09-12 2006-04-07 Methodes de traitement de la deficience du facteur de croissance de type insuline 1 (1gf-1)

Country Status (18)

Country Link
US (3) US7258864B2 (fr)
EP (2) EP2274978B1 (fr)
JP (1) JP4738337B2 (fr)
CN (2) CN1870893A (fr)
AT (1) ATE536186T1 (fr)
AU (1) AU2004291833B2 (fr)
CA (1) CA2538342C (fr)
DK (1) DK2274978T3 (fr)
ES (2) ES2541673T3 (fr)
HU (1) HUE027218T2 (fr)
IL (1) IL174209A (fr)
MA (1) MA28091A1 (fr)
NZ (1) NZ545940A (fr)
PL (1) PL2274978T3 (fr)
PT (1) PT2274978E (fr)
TN (1) TNSN06082A1 (fr)
WO (1) WO2005049792A2 (fr)
ZA (1) ZA200602183B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2274978B1 (fr) * 2003-09-12 2015-05-20 Tercica, Inc. Méthodes de traitement de la déficience du facteur de croissance de type insuline 1 (IGF-1)
JP2008545752A (ja) * 2005-06-02 2008-12-18 テルシカ インコーポレーティッド 成長障害を処置するための方法
CA2689549A1 (fr) * 2007-06-08 2008-12-18 Massachusetts Institute Of Technology Traitement du syndrome de rett et d'autres troubles
US20090177142A1 (en) 2008-01-09 2009-07-09 Smiths Medical Md, Inc Insulin pump with add-on modules
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
CA2737461A1 (fr) 2008-09-19 2010-03-25 Tandem Diabetes Care, Inc. Dispositif de mesure de la concentration d'un solute et procedes associes
CA2643529C (fr) * 2008-11-06 2019-05-21 Kenneth W. Adams Methode et composition permettant d'ameliorer la fonction erectile masculine
US8573027B2 (en) 2009-02-27 2013-11-05 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
WO2011011072A2 (fr) 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues au facteur-1 de croissance insulinomimétique (igf-1) présentant une substitution d'acide aminé en position 59
WO2011011071A2 (fr) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues au facteur-1 de croissance analogue à l'insuline (igf-1)
US8926561B2 (en) 2009-07-30 2015-01-06 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
EP2576834A4 (fr) * 2010-05-26 2013-11-20 Philadelphia Children Hospital Compositions et procédés pour le diagnostic et le traitement du déficit primaire en facteur de croissance analogue à l'insuline (pigfd) et de l'insuffisance staturale idiopathique (iss)
US20130302909A1 (en) * 2011-01-14 2013-11-14 Theratechnologies Inc. Assessment of igf-1 levels in hiv-infected subjects and uses thereof
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US10201656B2 (en) 2013-03-13 2019-02-12 Tandem Diabetes Care, Inc. Simplified insulin pump for type II diabetics
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9492608B2 (en) 2013-03-15 2016-11-15 Tandem Diabetes Care, Inc. Method and device utilizing insulin delivery protocols
WO2016100528A1 (fr) * 2014-12-16 2016-06-23 Puretein Bioscience Llc. Procédés d'augmentation de l'igf-1 dans le sérum d'un animal
WO2019075404A2 (fr) * 2017-10-13 2019-04-18 The Metrohealth System Igf-1 (facteur de croissance insulinique) en tant que thérapie pour arythmies cardiaques
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
KR102245539B1 (ko) * 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
US11872368B2 (en) 2018-04-10 2024-01-16 Tandem Diabetes Care, Inc. System and method for inductively charging a medical device

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (fr) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipides et composés tensio-actifs en phase aqueuse
NZ207842A (en) 1983-04-25 1988-02-12 Chiron Corp Production of human insulin-like growth factor (igf) using cdna
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3483949D1 (de) 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
ATE81779T1 (de) 1985-08-22 1992-11-15 Gropep Pty Ltd Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren.
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
ATE90690T1 (de) 1987-04-06 1993-07-15 Celtrix Pharma Menschliche somatomedin-traeger-proteinuntereinheiten und verfahren zu ihrer herstellung.
EP0288451B1 (fr) 1987-04-23 1994-08-10 Monsanto Company Sécrétion d'un facteur de croissance de type insuline dans l'Escherichia coli
US5057417A (en) 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
ATE116335T1 (de) 1987-12-24 1995-01-15 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
ATE132164T1 (de) 1988-04-12 1996-01-15 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
WO1991004014A1 (fr) 1989-09-21 1991-04-04 Synergen, Inc. Procede de transport de compositions a travers la barriere hemato-encephalique
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5210017A (en) 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5593844A (en) 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5198340A (en) 1991-01-17 1993-03-30 Genentech, Inc. Assay for free igf-i, igf-ii, and gh levels in body fluids
US5187151A (en) 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5206235A (en) 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
EP0597033B1 (fr) 1991-08-01 1997-04-09 Genentech, Inc. Igf-1 utilise pour ameliorer l'etat pathologique du systeme nerveux
EP0646178A1 (fr) 1992-06-04 1995-04-05 The Regents Of The University Of California Cassette d'expression avec des regious regulatrices fonctionnelles chez le mammifere hote
NZ255461A (en) 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
WO1995017423A1 (fr) 1993-12-23 1995-06-29 Novo Nordisk A/S Composes possedant des proprietes de liberation de l'hormone de croissance
AU683121B2 (en) 1993-12-23 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5646113A (en) * 1994-04-07 1997-07-08 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US6207640B1 (en) * 1994-04-07 2001-03-27 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5824642A (en) * 1994-04-07 1998-10-20 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
BRPI9608799B8 (pt) 1995-05-26 2019-11-05 Theratechnologies Inc análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica.
CA2224859A1 (fr) 1996-04-17 1997-10-23 Amitabh Gaur Inhibiteurs de ligands inhibant les proteines de liaison du facteur de croissance du type insuline et leurs procedes d'utilisation
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
JP2002535967A (ja) 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ変異体
EP2274978B1 (fr) * 2003-09-12 2015-05-20 Tercica, Inc. Méthodes de traitement de la déficience du facteur de croissance de type insuline 1 (IGF-1)

Also Published As

Publication number Publication date
US7258864B2 (en) 2007-08-21
AU2004291833B2 (en) 2010-08-26
NZ545940A (en) 2009-12-24
US7517530B2 (en) 2009-04-14
TNSN06082A1 (en) 2007-10-03
IL174209A0 (en) 2006-08-01
DK2274978T3 (en) 2015-06-15
CN102861321A (zh) 2013-01-09
CA2538342A1 (fr) 2005-06-02
ES2373783T3 (es) 2012-02-08
EP1667521A2 (fr) 2006-06-14
CN1870893A (zh) 2006-11-29
HUE027218T2 (en) 2016-10-28
PL2274978T3 (pl) 2015-11-30
ES2541673T3 (es) 2015-07-23
US8133862B2 (en) 2012-03-13
EP1667521B1 (fr) 2011-12-07
ZA200602183B (en) 2007-07-25
JP4738337B2 (ja) 2011-08-03
US20080058259A1 (en) 2008-03-06
EP1667521A4 (fr) 2008-07-02
CA2538342C (fr) 2013-01-08
IL174209A (en) 2012-12-31
US20050059598A1 (en) 2005-03-17
ATE536186T1 (de) 2011-12-15
WO2005049792A3 (fr) 2006-02-23
PT2274978E (pt) 2015-07-09
AU2004291833A1 (en) 2005-06-02
US20090270323A1 (en) 2009-10-29
EP2274978B1 (fr) 2015-05-20
EP2274978A1 (fr) 2011-01-19
WO2005049792A2 (fr) 2005-06-02
JP2007505140A (ja) 2007-03-08

Similar Documents

Publication Publication Date Title
MA28091A1 (fr) Methodes de traitement de la deficience du facteur de croissance de type insuline 1 (1gf-1)
Khandelwal et al. Conventional SLA and chemically modified SLA implants in patients with poorly controlled type 2 diabetes mellitus–a randomized controlled trial
Cho et al. Effects of aromatherapy on the anxiety, vital signs, and sleep quality of percutaneous coronary intervention patients in intensive care units
Harrington et al. Update on the evaluation and treatment of osteogenesis imperfecta
DE60336934D1 (de) Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheiten
WO1995027495A3 (fr) Traitement du syndrome d'insensibilite partielle a l'hormone de croissance
Rosen et al. The aging skeleton
Yang et al. Sihler-stain study of buccal nerve distribution and its clinical implications
Crescentini et al. Cognitive and brain reserve for mind-body therapeutic approaches in multiple sclerosis: a review
NO940180D0 (no) Anvendelse av IGF-I
Umei et al. Impact of mobilisation therapy on the haemodynamic and respiratory status of elderly intubated patients in an intensive care unit: A retrospective analysis
US6818665B2 (en) Treatment of obstructive sleep apnea
Ashley What are the characteristics of overweight and obese patients who achieve weight loss and what factors are most helpful? A quantitative and qualitative study of patients and interventions in a rural general practice
Gabopoulou et al. Epidural calcitonin: does it provide better postoperative analgesia? An analysis of the haemodynamic, endocrine, and nociceptive responses of salmon calcitonin and opioids in epidural anesthesia for hip arthroplasty surgery
Calarge et al. Selective serotonin reuptake inhibitors reduce longitudinal growth in risperidone-treated boys
Constans Plasma glucose goals and therapeutic management in elderly diabetic patients
Sargunam et al. Transient diplopia: a loco regional complication of inferior alveolar nerve block
ATE246511T1 (de) Behandlung des partiellen wachstumshormon- unempfindlichkeitssyndroms
WO2003045322A3 (fr) Methode permettant de traiter et de prevenir la pancreatite
Kulasegaram et al. End-of-Life care communication training programs for Long-Term care staff: A scoping review
Aksoy et al. Distribution and pattern of implant therapy in a part of the Turkish population
Jowsey et al. Long-term experience with fluoride and fluoride combination treatment of osteoporosis
Casanveva Consensus on the diagnosis and treatment of acromegaly
RU2365367C1 (ru) Способ лечения функциональной диспепсии
Lazdia et al. The Effect of Ozone Therapy on the Healing Process of Diabetic Mellitus Wounds at the DD Care Clinic of the Wound, Stoma and Continental Care Center, Padang City